Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

D-Dimer elevation and adverse outcomes JOURNAL OF THROMBOSIS AND THROMBOLYSIS Halaby, R., Popma, C. J., Cohen, A., Chi, G., Zacarkim, M. R., Romero, G., Goldhaber, S. Z., Hull, R., Hernandez, A., Mentz, R., Harrington, R., Lip, G., Peacock, F., Welker, J., Martin-Loeches, I., Daaboul, Y., Korjian, S., Gibson, C. M. 2015; 39 (1): 55-59

Abstract

D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adverse outcomes has received far less emphasis. An elevated D-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated D-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the D-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.

View details for DOI 10.1007/s11239-014-1101-6

View details for Web of Science ID 000348660300008

View details for PubMedID 25006010

View details for PubMedCentralID PMC4300425